Latest News

Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline

Advance™ technology-enabled solution enables R&D organizations to cut study timelines, deliver cost savings and reduce animal experimentation.

PHILADELPHIA, PA – (BUSINESS WIRE) – January 25, 2024 - Instem, a leading provider of IT solutions and services to the global life sciences market, announced today that its latest in silico solution offering known as Advance™ , is providing clients with a technology-enabled approach for assessing carcinogenicity based on the ICH S1B Weight of Evidence (WoE) Addendum.


Instem Now Part of ARCHIMED to Further Accelerate Growth and Impact

November 27, 2023 - Healthcare investment specialist ARCHIMED has the expertise, experience, enthusiasm and financial strength to fully back Instem’s ambitions.


Instem Announces New Software Solution to Support Updated Nitrosamines Guidance

September 28, 2023 - New Software Module Introduced to Support the Latest Regulatory-approved Carcinogenic Potency Categorization Approach (CPCA)


Instem Announces Transfer of ToxHub Platform and launch of Centrus®

May 15, 2023 - New powerful technology and data sharing suite provides a range of translational science solutions


Instem Unveils New Additions to its Leading Computational Toxicology Software Suite

November 2, 2022 - New functionality along with Enhanced Models to Deliver More Efficient and Comprehensive Predictions in Chemical Safety

View all news

 

 

 

Events

Exhibiting at SOT 2024

March 10 - 14, 2024

Salt Palace Convention Center, Salt Lake City, Booth #1401

Visit Conference Site

SOT Events Page


Solution Areas: In Silico, Preclinical Study Management, SEND


Proud to be presenting a Spotlight Presentation at the Clinical Data Disclosure, Transparency and Plain Language Summaries Event

March 19 - 20, 2024

Hilton Philadelphia at Penn’s Landing, Philadelphia, PA

Visit Conference Site


Solution Areas: Clinical Trial Analytics & Transparency

 

View all events